Cartesian Therapeutics (RNAC) FCF Margin: 2015-2025
Historic FCF Margin for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -3,737.17%.
- Cartesian Therapeutics' FCF Margin fell 585138.00% to -3,737.17% in Q3 2025 from the same period last year, while for Sep 2025 it was -6,315.12%, marking a year-over-year decrease of 621414.00%. This contributed to the annual value of -84.21% for FY2024, which is 11333.00% up from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' FCF Margin is -3,737.17%, which was up 44.64% from -6,750.34% recorded in Q2 2025.
- Cartesian Therapeutics' 5-year FCF Margin high stood at 2,114.21% for Q3 2024, and its period low was -6,750.34% during Q2 2025.
- In the last 3 years, Cartesian Therapeutics' FCF Margin had a median value of -188.74% in 2023 and averaged -968.26%.
- Per our database at Business Quant, Cartesian Therapeutics' FCF Margin surged by 225,488bps in 2024 and then plummeted by 670,033bps in 2025.
- Cartesian Therapeutics' FCF Margin (Quarterly) stood at -106.02% in 2021, then spiked by 3,421bps to -71.81% in 2022, then slumped by 21,068bps to -282.48% in 2023, then soared by 129,790bps to 1,015.42% in 2024, then slumped by 585,138bps to -3,737.17% in 2025.
- Its last three reported values are -3,737.17% in Q3 2025, -6,750.34% for Q2 2025, and -2,198.45% during Q1 2025.